Pharmaceutical - Antibiotics and Infectious diseases, Gastro-intestinals


Popular Filters

AstraZeneca gains rights to Ardelyx program; GSK returns cUTI candidate GSK2251052 to Anacor


Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning announced a worldwide exclusive licensing…

Anacor PharmaceuticalAntibiotics and Infectious diseasesArdelyxAstraZenecaGastro-intestinalsGenito-urinaryGlaxoSmithKlineGSK2251052LicensingNephrology and HepatologyPharmaceuticalRDX5791Research

Pharmaceutical majors unite in Japan to combat H. pylori


On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Regulatory briefs: Amitiza in Japan; Dificid in Canada; Eurartesim roll-out


Sucampo Pharmaceuticals (Nasdaq: SCMP) and Abbott Labs (NYSE: ABT) have received approval from the Ministry…

Abbott LaboratoriesAmitizaAntibiotics and Infectious diseasesAsia-PacificDificidEurartesimGastro-intestinalsMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulationSigma-TauSucampoTropical diseases

Back to top